Technology
Breakthrough in Microfluidic Reactor Design
Our team has developed a new reactor architecture that increases FDG synthesis efficiency by 15%.
Stay up to date with the latest developments in microfluidics and radiopharmacy.
Technology
Our team has developed a new reactor architecture that increases FDG synthesis efficiency by 15%.
Collaboration
We will test our 'on-demand' production systems in the clinical practice of the University Medical Center Utrecht.
Research
A whitepaper on the impact of point-of-care production on the availability of radiopharmaceuticals for PET diagnostics.
Event
Our CTO gave a keynote on eliminating transport losses due to radioactive decay.
Our microfluidic system is a compact device placed in a hospital pharmacy. It uses minuscule channels to perform the chemical synthesis of short-lived radiopharmaceuticals for PET scans 'on-demand' and automated, right next to the patient.
The biggest advantage is the elimination of transport losses due to radioactive decay. Traditionally, these isotopes are produced and transported centrally, with a significant portion of the activity already decaying before arrival. On-site production maximizes the usable dose for the patient.
Our systems are specifically developed for short-lived positron emitters essential for PET imaging, such as Fluorine-18 (¹⁸F) and Gallium-68 (⁶⁸Ga). The flexible design architecture allows for adaptation for other isotopes.
Yes, safety is a core design principle. The system is fully enclosed, automated, and provides multiple layers of radiation shielding and process monitoring. It complies with the stringent requirements for pharmaceutical production and nuclear safety.
The quality is equivalent or better. Microfluidics provides extremely precise control over reaction conditions (temperature, mixing), leading to a high and reproducible yield and purity of the final product, meeting all pharmacopoeia specifications.
We collaborate with progressive academic hospitals and nuclear medicine departments in the Netherlands and the EU to validate and implement our technology. Contact us via contact.html to discuss the possibilities for your institution.